Business Wire

RNA sequencing transformed: Oxford Nanopore introduces new cDNA Sequencing Kits

Share

Oxford Nanopore has launched new ‘109’ cDNA Kits for its real-time, scalable sequencing technology. The new kits provide high throughput whilst generating complete sequences of full-length cDNA strands, with a low input option of just 1ng PolyA+ RNA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190204005413/en/

The new cDNA sequencing method enables users to sequence whole transcriptomes to high coverage on a single MinION flow cell (10-15 million reads x full length transcripts), with substantially higher throughput capabilities on PromethION (more than 60 million reads x full length transcripts per flow cell), or smaller, rapid assays on Flongle. This facilitates new biological insights across a diverse range of applications.

Full-length, well-characterised cDNA transcripts for scientific research, health and industry

Oxford Nanopore’s new long-read cDNA sequencing solutions allow researchers to sequence millions of whole transcripts end-to-end in single reads. This enables users to simultaneously perform accurate isoform-level transcriptome characterisation, and differential gene expression profiling without any of the compromises on cost, quantitation, computational or workflow complexity required to achieve this on other short or long read sequencing platforms.

Deeper insight into the dynamics of the transcriptome are critical in enabling researchers across a broad range of fields to understand how the stable DNA ‘code’ of an organism is interpreted at a given moment in time. In healthcare, the identification of differentially spliced isoforms and fusion transcripts can inform disease diagnosis and treatment. RNA sequencing also provides a rapid, effective method of virus identification, and also has applications in environmental and agricultural science.

Jonathan Gӧke from the Genome Institute of Singapore said:

“We are working on identification of alternative gene isoforms and fusion genes in cancer, and the ability to generate reads that span the entire RNA can make a big difference. With nanopore long read cDNA sequencing kits we obtain a much more detailed view of which transcripts are generated."

Anthony Bayega from McGill University said:

“Nanopore cDNA Sequencing Kits have provided us with quick workflows, full-length quantitative transcripts, and eased our data analysis since complex statistical considerations that need to be taken for short-read data, where full-length resolution of genes is difficult to determine, are not necessary.”

in relation to his use of the PCR-cDNA Kit to study the transcriptome of the developing olive fly embryo.

Direct cDNA and PCR-cDNA options

The two new kits now available are Direct cDNA (SQK-DCS109) and PCR-cDNA (SQK-PCS109) Sequencing Kits. In combination with upgrades to the Oxford Nanopore sequencing platforms and software, nanopore cDNA sequencing delivers effective enrichment for full-length transcripts (PCR-cDNA). In the case of the Direct cDNA kit, PCR is not necessary — removing bias, whilst the cDNA- PCR kit enables high throughput from low RNA input (just 1 ng PolyA+ RNA) and provides the option of starting from total RNA. The kits, which require less than 5 hours sample preparation time end-to-end, with little of this representing hands-on time, are now available to buy in Oxford Nanopore’s store.

The new cDNA kits are available to use on all Oxford Nanopore devices, from the pocket-sized MinION to the benchtop GridION and the high-throughput PromethION. This allows users of any scale to generate very high yields of transcriptomic data for high-resolution novel isoform discovery, identification of low copy number transcripts and de novo sequencing of entire transcriptomes to high coverage. Small, rapid devices such as Flongle are also ideal for targeted cDNA sequencing of specific transcripts.

In addition to cDNA sequencing, Oxford Nanopore also uniquely offers direct RNA analysis kits, allowing users to sequence RNA without the need to convert to cDNA.

https://nanoporetech.com/about-us/news/rna-sequencing-transformed-oxford-nanopore-introduces-new-cdna-sequencing-kits

Contact information

Oxford Nanopore
Zoe McDougall
media@nanoporetech.com
Website: https://nanoporetech.com/
Twitter @nanopore
WeChat: nanoporetech

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gilead Announces Latest Data in Ongoing HIV Cure Research Program23.7.2019 20:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented results from two studies of investigational toll-like receptor 7 (TLR7) agonists as part of an HIV cure research program. The Phase 1 and preclinical study results demonstrate that the TLR7 agonists vesatolimod (GS-9620) and GS-986 can induce immune activation and follow earlier preclinical research suggesting that TLR7 agonists can potentially lead to viral remission, as part of combination regimens. The HIV viral reservoir is present even in virologically suppressed individuals and its elimination is regarded as a main obstacle to achieving a cure. The data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “While treatments have improved dramatically, people living with HIV still face a lifetime of therapy and potential complications. That reality drives our ongoing pursuit of a cure for HIV,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses

Moody’s Analytics Wins Best Reporting System Provider in Waters Rankings23.7.2019 15:30:00 CESTPress release

Moody’s Analytics, a global provider of financial intelligence, has won the award for Best Reporting System Provider in the 2019 Waters Rankings. We earned this recognition for our regulatory reporting solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005679/en/ For banks and insurers, staying on top of regulatory changes is critical. Our end-to-end solution handles the entire reporting process, producing 3,000 different regulatory reports covering more than 50 jurisdictions. It automatically delivers all required updates well in advance of the relevant deadlines and makes it easy for clients to review, adjust, audit, and validate their reports. The Moody’s Analytics regulatory surveillance team boasts a wealth of experience in both local and international domains going back decades. They monitor more than 100 supervisor websites to ensure that our clients receive the updates they need in a timely fashion. “Regu

Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada®23.7.2019 15:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP). In a sub-analysis of the DISCOVER trial, Descovy reached intracellular drug concentration levels above the estimated protective threshold significantly more quickly than Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets; F/TDF), and additional pharmacokinetic data confirm that these drug concentration levels persist longer than Truvada. The results were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “Gilead is committed to driving advances in HIV prevention and supporting broader public health initiatives that are designed to reduce HIV infections,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “These

Velodyne Lidar Acquires Mapper.ai for ADAS Launch23.7.2019 15:00:00 CESTPress release

Velodyne Lidar, Inc. today announced it has acquired mapping and localization software as well as intellectual property assets from Mapper.ai. Mapper technology will enable Velodyne to accelerate development of Vella™, breakthrough software that establishes its directional view Velarray™ lidar sensor. The Velarray is the first solid-state Velodyne lidar sensor that is embeddable and fits behind a windshield, as an integral component for superior, more effective advanced driver assistance systems (ADAS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190723005257/en/ In addition to ADAS, Velodyne will incorporate Mapper technology into lidar-centric solutions for other emerging applications, including autonomous vehicles, last-mile delivery services, security, smart cities, smart agriculture, robotics, and unmanned aerial vehicles. (Photo: Business Wire) Mapper’s entire leadership and engineering teams will join Velodyne, bol

Wealthy Americans are increasingly willing to invest, new UBS survey finds23.7.2019 14:12:00 CESTPress release

US high net worth individuals and business owners are expressing growing intentions to invest as US markets continue to hit record highs in 2019, according to UBS Global Wealth Management's new quarterly Investor Sentiment survey. The survey, which polled more than 3,800 wealthy investors and entrepreneurs in 17 countries, also shows US investors remain positive on the U.S. stock market but continue to rank politics and the national debt as top concerns. Fifty percent of US investors see a diversified portfolio as a hedge against US-China trade tensions specifically, in line with UBS GWM's own views, compared with 41% who favor cash. Filippo Ilardi, US Client Strategy Officer at UBS Global Wealth Management, says: "We are pleased to see a substantial increase in investors willing to put more money in the market. Wealthy Americans are concerned about the political environment and US-China trade tensions but we are encouraged that they see diversification as an important way of managing

Andersen Global Expands into Ghana23.7.2019 13:30:00 CESTPress release

Ghana law firm, Sam Okudzeto & Associates, signed a collaboration agreement with Andersen Global, marking Andersen Global’s presence in 13 African countries and over 51 countries worldwide. Located in the capital of Accra, Sam Okudzeto & Associates is one of the largest law firms in Ghana. For the past 48 years, the firm has provided legal advice and guidance in the corporate and commercial areas, including patents and trademarks, mergers and acquisition, tax advisory, corporate banking, international trade and investment, debt recovery, mining and mineral law, industrial and labor, aviation, maritime law, petroleum oil and gas, and intellectual property. Sam Okudzeto & Associates founder and Managing Partner, Sam Okudzeto and Nene Amegatcher, have led the team since the establishment of the firm until Nene Amegatcher was elevated to the Supreme Court. The firm now has four partners and 18 lawyers who have gained international reputation for their keen knowledge and experience with Alt